Situs Corporation names Shawn Scranton director of Clinical ResearchSitus Corporation - Press Release : 04/27/00
This is the Situs Corporation's LogoImportant Notice
Home Executive Summary Markets
...SITUS CORPORATION NAMES SHAWN SCRANTON DIRECTOR OF CLINICAL RESEARCH
names Shawn Scranton
director of Clinical Research
SAN DIEGO, CA – January 24, 2001 – Situs Corporation
, developer of a novel drug delivery platform for the administration of intravesical (bladder) drugs, today announced the appointment of Shawn A. Scranton Pharm.D. as Director of Clinical Research.Dr. Scranton brings to Situs experience in the pharmaceutical and clinical pharmacotherapy industries, according to Tate Scott, President and CEO of Situs.
...Most recently Dr. Scranton served as Senior Manager of Medical Research at Dura Pharmaceuticals.
tenure at Dura he
was responsible for study design, scientific conduct, and data analysis of numerous Phase I – IV clinical trials.Prior to that, he was an Assistant Professor at the University of Houston, College of Pharmacy and conducted clinical research in the area of cardiovascular pharmacodynamics.Dr. Scranton
Doctor of Pharmacy from the University of the Pacific School of Pharmacy
, where he
later completed a post-doctoral fellowship in cardiovascular pharmacotherapy.He also completed a clinical pharmacy residency at Veterans Affairs Medical Center in San Diego and worked as a Clinical Pharmacist at several leading hospitals in Houston and San Diego. Situs
is a combination specialty pharmaceutical and drug delivery device manufacturer pioneering an intravesical drug delivery platform.The Company's proprietary UROS Infusor is one of the most unique methods of drug delivery and provides a solution for the inadequacies of conventional therapies.In addition to the treatment of overactive bladder, other applications include chemotherapeutic agents for bladder cancer, hormones for genitourinary conditions and analgesics for pain.The Company is headquartered in Solana Beach, California.
This press release contains forward-looking statements, such as projecting future performance of products and materials, which include some risk and uncertainty.